Superworth

Entrada Therapeutics free cash flow TRDA

Cash from operations less capital spending, by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
−$134.4M
Latest quarter, Q2 FY26
−$32.5M
Fiscal year 2025
−$129.6M

Entrada Therapeutics' free cash flow was −$134.4M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$32.5M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$129.6Mn/a
FY2024−$44.7M−133%
FY2023$134.2Mn/a
FY2022−$96.7Mn/a
FY2021−$55.4Mn/a
FY2020n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$32.5Mn/a−$134.4M
Q1 FY26−$41.7Mn/a−$131.6M
Q4 FY25−$32Mn/a−$129.6M
Q3 FY25−$28.1Mn/a−$129.8M
Q2 FY25−$29.8M−177%−$126.6M
Q1 FY25−$39.7Mn/a−$58M
Q4 FY24−$32.2Mn/a−$44.7M
Q3 FY24−$24.9Mn/a−$17.5M
Q2 FY24$38.8Mn/a−$18.5M
Q1 FY24−$26.4M−113%−$93.9M
Q4 FY23−$5Mn/a$134.2M
Q3 FY23−$25.9Mn/a$111.2M

Against its peers

Companies in Drug Manufacturers - General nearest Entrada Therapeutics' size, closest first, today.

CompanyFree cash flow yield
TRDAEntrada Therapeutics−78.2%
NATRNatures Sunshine Products8.5%
LFVNLifevantage9.1%
SPROSpero Therapeuticsn/m
ARVNArvinas−43.7%
PBYIPuma Biotechnology7.2%
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics5.6%
CRMDCorMedixn/m
ATNMActinium Pharmaceuticalsn/m
COLLCollegium Pharmaceuticaln/m
Peer median7.2%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Entrada Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.